Jeena Sikho Lifecare Reports Strong FY26 Growth, Recommends ₹4.50 Dividend

Revenue from operations jumped 71% to ₹801.35 crore, profit surged 178% to ₹222.18 crore.

Reader Takeaway: Strong profit and revenue growth are positives, but pending acquisition and regulatory costs pose risks.

What just happened

Jeena Sikho Lifecare Ltd announced its audited financial results for the quarter and year ended March 31, 2026. The company's board has recommended a final dividend of ₹4.50 per equity share, with a face value of ₹2. This is the first time the company has presented consolidated financial statements, showing its subsidiaries' performance. The statutory auditors have issued an unmodified opinion on these results.

Why this matters

The company has demonstrated significant growth in its top and bottom lines for FY2026 compared to FY2025. Revenue from operations increased by 71% to ₹801.35 crore, while profit for the period saw a substantial rise of 178% to ₹222.18 crore. The maiden consolidated financial statements provide a more comprehensive view of the company's financial health and operational scope, including subsidiaries like Jeena Green Resources Private Limited.

The backstory

Jeena Sikho Lifecare operates in the Ayurvedic products/medicines and healthcare services sectors. In FY2026, the Ayurvedic products segment generated ₹415.68 crore, while Ayurvedic healthcare services contributed ₹383.40 crore. This shows a balanced revenue stream across its core business areas.

What changes now

Shareholders will be looking forward to the final dividend payout, subject to approval. The presentation of consolidated financials is expected to enhance transparency and investor confidence. The company has also re-appointed M/s Forvis Mazars LLP as its internal auditor for FY2026-27.

Risks to watch

Jeena Sikho Lifecare recognized an incremental financial impact of ₹1.25 crore due to the upcoming implementation of new Labour Codes from November 2025. Additionally, the completion of a 51% stake acquisition in 'Back to Roots Ayurveda' is pending regulatory formalities in Abu Dhabi, which could impact future growth.

Peer comparison

While specific peer financial data for FY2026 is not immediately available, Jeena Sikho Lifecare's reported revenue growth of 71% and profit growth of 178% indicates a strong performance within the Ayurvedic healthcare sector.

Context metrics (time-bound)

• Revenue from operations in FY2026: ₹801.35 crore (vs. ₹469.07 crore in FY2025).
• Profit for the period in FY2026: ₹222.18 crore (vs. ₹79.94 crore in FY2025).
• Final dividend recommended: ₹4.50 per equity share.

What to track next

Investors should closely monitor the completion of the 'Back to Roots Ayurveda' acquisition and its integration. Keeping an eye on the impact of new Labour Codes and the company's continued performance in its Ayurvedic products and healthcare services segments will also be crucial.